5-Fluorouracil and alpha-interferon in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a major cause of mortality worldwide, and no effective systematic therapy currently exists. Recombinant alpha-interferon (IFN) has been suggested to have some antitumor efficacy in this illness, and synergism with 5-fluorouracil (5-FU) has been reported in several g...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1996-04, Vol.19 (2), p.136-139 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 139 |
|---|---|
| container_issue | 2 |
| container_start_page | 136 |
| container_title | American journal of clinical oncology |
| container_volume | 19 |
| creator | STUART, K TESSITORE, J HUBERMAN, M |
| description | Hepatocellular carcinoma (HCC) is a major cause of mortality worldwide, and no effective systematic therapy currently exists. Recombinant alpha-interferon (IFN) has been suggested to have some antitumor efficacy in this illness, and synergism with 5-fluorouracil (5-FU) has been reported in several gastrointestinal malignancies. We therefore treated 10 patients with advanced HCC with combination therapy consisting of 5-FU 750/mg/m(2) weekly and IFN 9 X 10(6) units three times weekly. Toxicity was substantial in this cirrhotic population, and included mucositis as well as neurologic and hematologic side effects. There were no sustained antitumor responses. Median survival among this heavily pretreated population was 10 months. We were therefore unable to demonstrate any significant benefit to treatment with 5-FU and IFN in patients with HCC. |
| doi_str_mv | 10.1097/00000421-199604000-00009 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00000421_199604000_00009</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8610636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-7f467078f9f04353d5c88be1ede927d3edcd9596d5a5ecdb3ff9a434983454f33</originalsourceid><addsrcrecordid>eNo9kEtLw0AQxxdRaq1-BCEHr6u7mX2eRIpVoeBFwVuY7oNGtknYJAe_vamtncsw_8ccfoQUnN1zZvUD248oOeXWKiamg-4Ve0bmXIKmQsLXOZmzUmsKGspLctX331NCKqZnZGYUZwrUnDxKukpjm9sxo6tTgY0vMHVbpHUzhBxDbpuibopt6HBoXUhpTJgLh9nVTbvDa3IRMfXh5rgX5HP1_LF8pev3l7fl05o6ADtQHYXSTJtoIxMgwUtnzCbw4IMttYfgnbfSKi9RBuc3EKNFAcIaEFJEgAUxh78ut32fQ6y6XO8w_1ScVXsk1T-S6oTkT7JT9fZQ7cbNLvhT8chg8u-OPvYOU8zYuLo_xYCBMbaEX83DaRA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>5-Fluorouracil and alpha-interferon in hepatocellular carcinoma</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>STUART, K ; TESSITORE, J ; HUBERMAN, M</creator><creatorcontrib>STUART, K ; TESSITORE, J ; HUBERMAN, M</creatorcontrib><description>Hepatocellular carcinoma (HCC) is a major cause of mortality worldwide, and no effective systematic therapy currently exists. Recombinant alpha-interferon (IFN) has been suggested to have some antitumor efficacy in this illness, and synergism with 5-fluorouracil (5-FU) has been reported in several gastrointestinal malignancies. We therefore treated 10 patients with advanced HCC with combination therapy consisting of 5-FU 750/mg/m(2) weekly and IFN 9 X 10(6) units three times weekly. Toxicity was substantial in this cirrhotic population, and included mucositis as well as neurologic and hematologic side effects. There were no sustained antitumor responses. Median survival among this heavily pretreated population was 10 months. We were therefore unable to demonstrate any significant benefit to treatment with 5-FU and IFN in patients with HCC.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-199604000-00009</identifier><identifier>PMID: 8610636</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Antimetabolites, Antineoplastic - administration & dosage ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic agents ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Ataxia - chemically induced ; Biological and medical sciences ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - therapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Disease Progression ; Drug Administration Schedule ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Fluorouracil - therapeutic use ; Headache - chemically induced ; Humans ; Infusions, Intravenous ; Injections, Subcutaneous ; Interferon Type I - administration & dosage ; Interferon Type I - adverse effects ; Interferon Type I - therapeutic use ; Liver Cirrhosis - physiopathology ; Liver Neoplasms - drug therapy ; Liver Neoplasms - therapy ; Male ; Medical sciences ; Middle Aged ; Mucous Membrane - drug effects ; Neutropenia - chemically induced ; Pharmacology. Drug treatments ; Recombinant Proteins ; Remission Induction ; Survival Rate</subject><ispartof>American journal of clinical oncology, 1996-04, Vol.19 (2), p.136-139</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-7f467078f9f04353d5c88be1ede927d3edcd9596d5a5ecdb3ff9a434983454f33</citedby><cites>FETCH-LOGICAL-c339t-7f467078f9f04353d5c88be1ede927d3edcd9596d5a5ecdb3ff9a434983454f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3038892$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8610636$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STUART, K</creatorcontrib><creatorcontrib>TESSITORE, J</creatorcontrib><creatorcontrib>HUBERMAN, M</creatorcontrib><title>5-Fluorouracil and alpha-interferon in hepatocellular carcinoma</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>Hepatocellular carcinoma (HCC) is a major cause of mortality worldwide, and no effective systematic therapy currently exists. Recombinant alpha-interferon (IFN) has been suggested to have some antitumor efficacy in this illness, and synergism with 5-fluorouracil (5-FU) has been reported in several gastrointestinal malignancies. We therefore treated 10 patients with advanced HCC with combination therapy consisting of 5-FU 750/mg/m(2) weekly and IFN 9 X 10(6) units three times weekly. Toxicity was substantial in this cirrhotic population, and included mucositis as well as neurologic and hematologic side effects. There were no sustained antitumor responses. Median survival among this heavily pretreated population was 10 months. We were therefore unable to demonstrate any significant benefit to treatment with 5-FU and IFN in patients with HCC.</description><subject>Antimetabolites, Antineoplastic - administration & dosage</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Ataxia - chemically induced</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Disease Progression</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Fluorouracil - therapeutic use</subject><subject>Headache - chemically induced</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Injections, Subcutaneous</subject><subject>Interferon Type I - administration & dosage</subject><subject>Interferon Type I - adverse effects</subject><subject>Interferon Type I - therapeutic use</subject><subject>Liver Cirrhosis - physiopathology</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mucous Membrane - drug effects</subject><subject>Neutropenia - chemically induced</subject><subject>Pharmacology. Drug treatments</subject><subject>Recombinant Proteins</subject><subject>Remission Induction</subject><subject>Survival Rate</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLw0AQxxdRaq1-BCEHr6u7mX2eRIpVoeBFwVuY7oNGtknYJAe_vamtncsw_8ccfoQUnN1zZvUD248oOeXWKiamg-4Ve0bmXIKmQsLXOZmzUmsKGspLctX331NCKqZnZGYUZwrUnDxKukpjm9sxo6tTgY0vMHVbpHUzhBxDbpuibopt6HBoXUhpTJgLh9nVTbvDa3IRMfXh5rgX5HP1_LF8pev3l7fl05o6ADtQHYXSTJtoIxMgwUtnzCbw4IMttYfgnbfSKi9RBuc3EKNFAcIaEFJEgAUxh78ut32fQ6y6XO8w_1ScVXsk1T-S6oTkT7JT9fZQ7cbNLvhT8chg8u-OPvYOU8zYuLo_xYCBMbaEX83DaRA</recordid><startdate>19960401</startdate><enddate>19960401</enddate><creator>STUART, K</creator><creator>TESSITORE, J</creator><creator>HUBERMAN, M</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19960401</creationdate><title>5-Fluorouracil and alpha-interferon in hepatocellular carcinoma</title><author>STUART, K ; TESSITORE, J ; HUBERMAN, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-7f467078f9f04353d5c88be1ede927d3edcd9596d5a5ecdb3ff9a434983454f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antimetabolites, Antineoplastic - administration & dosage</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Ataxia - chemically induced</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Disease Progression</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Fluorouracil - therapeutic use</topic><topic>Headache - chemically induced</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Injections, Subcutaneous</topic><topic>Interferon Type I - administration & dosage</topic><topic>Interferon Type I - adverse effects</topic><topic>Interferon Type I - therapeutic use</topic><topic>Liver Cirrhosis - physiopathology</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mucous Membrane - drug effects</topic><topic>Neutropenia - chemically induced</topic><topic>Pharmacology. Drug treatments</topic><topic>Recombinant Proteins</topic><topic>Remission Induction</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STUART, K</creatorcontrib><creatorcontrib>TESSITORE, J</creatorcontrib><creatorcontrib>HUBERMAN, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STUART, K</au><au>TESSITORE, J</au><au>HUBERMAN, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5-Fluorouracil and alpha-interferon in hepatocellular carcinoma</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1996-04-01</date><risdate>1996</risdate><volume>19</volume><issue>2</issue><spage>136</spage><epage>139</epage><pages>136-139</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>Hepatocellular carcinoma (HCC) is a major cause of mortality worldwide, and no effective systematic therapy currently exists. Recombinant alpha-interferon (IFN) has been suggested to have some antitumor efficacy in this illness, and synergism with 5-fluorouracil (5-FU) has been reported in several gastrointestinal malignancies. We therefore treated 10 patients with advanced HCC with combination therapy consisting of 5-FU 750/mg/m(2) weekly and IFN 9 X 10(6) units three times weekly. Toxicity was substantial in this cirrhotic population, and included mucositis as well as neurologic and hematologic side effects. There were no sustained antitumor responses. Median survival among this heavily pretreated population was 10 months. We were therefore unable to demonstrate any significant benefit to treatment with 5-FU and IFN in patients with HCC.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>8610636</pmid><doi>10.1097/00000421-199604000-00009</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1996-04, Vol.19 (2), p.136-139 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00000421_199604000_00009 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Ataxia - chemically induced Biological and medical sciences Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Disease Progression Drug Administration Schedule Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Fluorouracil - therapeutic use Headache - chemically induced Humans Infusions, Intravenous Injections, Subcutaneous Interferon Type I - administration & dosage Interferon Type I - adverse effects Interferon Type I - therapeutic use Liver Cirrhosis - physiopathology Liver Neoplasms - drug therapy Liver Neoplasms - therapy Male Medical sciences Middle Aged Mucous Membrane - drug effects Neutropenia - chemically induced Pharmacology. Drug treatments Recombinant Proteins Remission Induction Survival Rate |
| title | 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T00%3A17%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5-Fluorouracil%20and%20alpha-interferon%20in%20hepatocellular%20carcinoma&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=STUART,%20K&rft.date=1996-04-01&rft.volume=19&rft.issue=2&rft.spage=136&rft.epage=139&rft.pages=136-139&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-199604000-00009&rft_dat=%3Cpubmed_cross%3E8610636%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8610636&rfr_iscdi=true |